Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.
作者信息
Yüzbaşıoğlu Mebrure Burçak, Eşkazan Ahmet Emre
机构信息
Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
出版信息
Expert Opin Drug Saf. 2021 Apr;20(4):379-381. doi: 10.1080/14740338.2021.1867103. Epub 2021 Jan 8.
Abstract
摘要
相似文献
1
Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.慢性髓性白血病患者中与博舒替尼相关的胸腔积液
Expert Opin Drug Saf. 2021 Apr;20(4):379-381. doi: 10.1080/14740338.2021.1867103. Epub 2021 Jan 8.
2
The safety of Bosutinib for the treatment of chronic myeloid leukemia.波舒替尼治疗慢性髓性白血病的安全性。
Expert Opin Drug Saf. 2017 Oct;16(10):1203-1209. doi: 10.1080/14740338.2017.1363176. Epub 2017 Sep 5.
3
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.在真实世界实践中，使用博舒替尼治疗的慢性髓性白血病患者心血管毒性易感性的发生率和评估。
Ann Hematol. 2019 Aug;98(8):1885-1890. doi: 10.1007/s00277-019-03705-y. Epub 2019 May 1.
4
Bosutinib. Chronic myeloid leukaemia in treatment failure: major toxicity.博舒替尼。治疗失败的慢性髓性白血病：主要毒性。
Prescrire Int. 2014 Jul;23(151):177.
5
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.博舒替尼用于达沙替尼治疗期间发生胸腔积液的慢性期慢性粒细胞白血病患者的疗效和安全性
Ann Hematol. 2019 Nov;98(11):2609-2611. doi: 10.1007/s00277-019-03802-y. Epub 2019 Sep 16.
6
Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.新型双重Src 和 Abl 激酶抑制剂博舒替尼治疗慢性髓性白血病的研究进展。
Expert Rev Anticancer Ther. 2012 Sep;12(9):1121-7. doi: 10.1586/era.12.84.
7
A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).对于先前治疗耐药和/或不耐受的慢性髓性白血病患者，使用较低初始剂量的博舒替尼：一项单臂、多中心、2 期试验（BOGI 试验）。
Int J Hematol. 2024 Oct;120(4):492-500. doi: 10.1007/s12185-024-03830-z. Epub 2024 Aug 13.
8
Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.达沙替尼导致肺部毒性后，使用博舒替尼出现肺动脉高压和胸腔积液恶化。
Eur Respir J. 2016 Nov;48(5):1517-1519. doi: 10.1183/13993003.01410-2016. Epub 2016 Oct 6.
9
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.博舒替尼治疗对费城染色体阳性白血病患者肾功能的影响。
Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):684-695.e6. doi: 10.1016/j.clml.2017.06.001. Epub 2017 Jun 17.
10
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.一项在健康成年受试者中进行的、评估波舒替尼（SKI-606）安全性、耐受性和药代动力学的 I 期递增单剂量研究。
Cancer Chemother Pharmacol. 2012 Jan;69(1):221-7. doi: 10.1007/s00280-011-1688-7. Epub 2011 Jun 21.
引用本文的文献
1
Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.基于 FDA 不良事件报告系统（FAERS）的 BCR::ABL1 抑制剂治疗患者的液体潴留相关不良事件：一项回顾性药物警戒研究。
BMJ Open. 2023 Aug 3;13(8):e071456. doi: 10.1136/bmjopen-2022-071456.
Zotero 插件